Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 124

1.

New directions in clinical trials for frontotemporal lobar degeneration: Methods and outcome measures.

Boxer AL, Gold M, Feldman H, Boeve BF, Dickinson SL, Fillit H, Ho C, Paul R, Pearlman R, Sutherland M, Verma A, Arneric SP, Alexander BM, Dickerson BC, Dorsey ER, Grossman M, Huey ED, Irizarry MC, Marks WJ, Masellis M, McFarland F, Niehoff D, Onyike CU, Paganoni S, Panzara MA, Rockwood K, Rohrer JD, Rosen H, Schuck RN, Soares HD, Tatton N.

Alzheimers Dement. 2020 Jan;16(1):131-143. doi: 10.1016/j.jalz.2019.06.4956. Epub 2020 Jan 6.

PMID:
31668596
2.

Regulatory-accepted drug development tools are needed to accelerate innovative CNS disease treatments.

Arnerić SP, Kern VD, Stephenson DT.

Biochem Pharmacol. 2018 May;151:291-306. doi: 10.1016/j.bcp.2018.01.043. Epub 2018 Feb 1. Review.

3.

Concise informed consent to increase data and biospecimen access may accelerate innovative Alzheimer's disease treatments.

Hake AM, Dacks PA, Arnerić SP; CAMD ICF working group.

Alzheimers Dement (N Y). 2017 Sep 1;3(4):536-541. doi: 10.1016/j.trci.2017.08.003. eCollection 2017 Nov. Review.

4.

Accelerating drug development for Alzheimer's disease through the use of data standards.

Neville J, Kopko S, Romero K, Corrigan B, Stafford B, LeRoy E, Broadbent S, Cisneroz M, Wilson E, Reiman E, Vanderstichele H, Arnerić SP, Stephenson D.

Alzheimers Dement (N Y). 2017 Apr 15;3(2):273-283. doi: 10.1016/j.trci.2017.03.006. eCollection 2017 Jun.

5.

Biometric monitoring devices for assessing end points in clinical trials: developing an ecosystem.

Arnerić SP, Cedarbaum JM, Khozin S, Papapetropoulos S, Hill DL, Ropacki M, Rhodes J, Dacks PA, Hudson LD, Gordon MF, Kern VD, Romero K, Vradenburg G, Au R, Karlin DR, Facheris MF, Fitzer-Attas CJ, Vitolo OV, Wang J, Miller BM, Kaye JA.

Nat Rev Drug Discov. 2017 Oct;16(10):736. doi: 10.1038/nrd.2017.153. Epub 2017 Sep 22. No abstract available.

PMID:
28935908
6.

Apolipoprotein E Genotype and Sex Risk Factors for Alzheimer Disease: A Meta-analysis.

Neu SC, Pa J, Kukull W, Beekly D, Kuzma A, Gangadharan P, Wang LS, Romero K, Arneric SP, Redolfi A, Orlandi D, Frisoni GB, Au R, Devine S, Auerbach S, Espinosa A, Boada M, Ruiz A, Johnson SC, Koscik R, Wang JJ, Hsu WC, Chen YL, Toga AW.

JAMA Neurol. 2017 Oct 1;74(10):1178-1189. doi: 10.1001/jamaneurol.2017.2188.

7.

Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: A View of the Regulatory Science Qualification Landscape from the Coalition Against Major Diseases CSF Biomarker Team.

Arnerić SP, Batrla-Utermann R, Beckett L, Bittner T, Blennow K, Carter L, Dean R, Engelborghs S, Genius J, Gordon MF, Hitchcock J, Kaplow J, Luthman J, Meibach R, Raunig D, Romero K, Samtani MN, Savage M, Shaw L, Stephenson D, Umek RM, Vanderstichele H, Willis B, Yule S.

J Alzheimers Dis. 2017;55(1):19-35. Review.

8.

Tailoring chronic pain treatments for the elderly: are we prepared for the challenge?

Arneric SP, Laird JM, Chappell AS, Kennedy JD.

Drug Discov Today. 2014 Jan;19(1):8-17. doi: 10.1016/j.drudis.2013.08.017. Epub 2013 Aug 31. Review.

PMID:
24001595
9.

Characterization of the substituted N-triazole oxindole TROX-1, a small-molecule, state-dependent inhibitor of Ca(V)2 calcium channels.

Swensen AM, Herrington J, Bugianesi RM, Dai G, Haedo RJ, Ratliff KS, Smith MM, Warren VA, Arneric SP, Eduljee C, Parker D, Snutch TP, Hoyt SB, London C, Duffy JL, Kaczorowski GJ, McManus OB.

Mol Pharmacol. 2012 Mar;81(3):488-97. doi: 10.1124/mol.111.075226. Epub 2011 Dec 21.

PMID:
22188924
10.

Evolving cancer pain treatments: rational approaches to improve the quality of life for cancer patients.

Knopp KL, Nisenbaum ES, Arneric SP.

Curr Pharm Biotechnol. 2011 Oct;12(10):1627-43. Review.

PMID:
21466450
11.

A novel slow-inactivation-specific ion channel modulator attenuates neuropathic pain.

Hildebrand ME, Smith PL, Bladen C, Eduljee C, Xie JY, Chen L, Fee-Maki M, Doering CJ, Mezeyova J, Zhu Y, Belardetti F, Pajouhesh H, Parker D, Arneric SP, Parmar M, Porreca F, Tringham E, Zamponi GW, Snutch TP.

Pain. 2011 Apr;152(4):833-43. doi: 10.1016/j.pain.2010.12.035. Epub 2011 Feb 23.

PMID:
21349638
12.

Analgesic effects of a substituted N-triazole oxindole (TROX-1), a state-dependent, voltage-gated calcium channel 2 blocker.

Abbadie C, McManus OB, Sun SY, Bugianesi RM, Dai G, Haedo RJ, Herrington JB, Kaczorowski GJ, Smith MM, Swensen AM, Warren VA, Williams B, Arneric SP, Eduljee C, Snutch TP, Tringham EW, Jochnowitz N, Liang A, Euan MacIntyre D, McGowan E, Mistry S, White VV, Hoyt SB, London C, Lyons KA, Bunting PB, Volksdorf S, Duffy JL.

J Pharmacol Exp Ther. 2010 Aug;334(2):545-55. doi: 10.1124/jpet.110.166363. Epub 2010 May 3.

PMID:
20439438
13.

Treatments for neuropathic pain differentially affect delayed matching accuracy by macaques: effects of amitriptyline and gabapentin.

Buccafusco JJ, Terry AV Jr, Vazdarjanova A, Snutch TP, Arneric SP.

Pain. 2010 Mar;148(3):446-53. doi: 10.1016/j.pain.2009.12.003. Epub 2010 Jan 25.

PMID:
20092945
14.

A fluorescence-based high-throughput screening assay for the identification of T-type calcium channel blockers.

Belardetti F, Tringham E, Eduljee C, Jiang X, Dong H, Hendricson A, Shimizu Y, Janke DL, Parker D, Mezeyova J, Khawaja A, Pajouhesh H, Fraser RA, Arneric SP, Snutch TP.

Assay Drug Dev Technol. 2009 Jun;7(3):266-80. doi: 10.1089/adt.2009.191.

PMID:
19530894
15.

8-(4-Methoxyphenyl)pyrazolo[1,5-a]-1,3,5-triazines: selective and centrally active corticotropin-releasing factor receptor-1 (CRF1) antagonists.

Gilligan PJ, He L, Clarke T, Tivitmahaisoon P, Lelas S, Li YW, Heman K, Fitzgerald L, Miller K, Zhang G, Marshall A, Krause C, McElroy J, Ward K, Shen H, Wong H, Grossman S, Nemeth G, Zaczek R, Arneric SP, Hartig P, Robertson DW, Trainor G.

J Med Chem. 2009 May 14;52(9):3073-83. doi: 10.1021/jm9000242.

PMID:
19361210
16.

Synthesis and structure-activity relationships of 8-(pyrid-3-yl)pyrazolo[1,5-a]-1,3,5-triazines: potent, orally bioavailable corticotropin releasing factor receptor-1 (CRF1) antagonists.

Gilligan PJ, Clarke T, He L, Lelas S, Li YW, Heman K, Fitzgerald L, Miller K, Zhang G, Marshall A, Krause C, McElroy JF, Ward K, Zeller K, Wong H, Bai S, Saye J, Grossman S, Zaczek R, Arneric SP, Hartig P, Robertson D, Trainor G.

J Med Chem. 2009 May 14;52(9):3084-92. doi: 10.1021/jm900025h.

PMID:
19361209
17.

Role of voltage-gated calcium channels in ascending pain pathways.

Zamponi GW, Lewis RJ, Todorovic SM, Arneric SP, Snutch TP.

Brain Res Rev. 2009 Apr;60(1):84-9. doi: 10.1016/j.brainresrev.2008.12.021. Epub 2008 Dec 31. Review.

18.

Neuroimaging of pain: advances and future prospects.

Stephenson DT, Arneric SP.

J Pain. 2008 Jul;9(7):567-79. doi: 10.1016/j.jpain.2008.02.008. Epub 2008 May 2. Review.

PMID:
18455479
19.

Neuronal nicotinic receptors: a perspective on two decades of drug discovery research.

Arneric SP, Holladay M, Williams M.

Biochem Pharmacol. 2007 Oct 15;74(8):1092-101. Epub 2007 Jun 26. Review.

PMID:
17662959
20.

Discovery of N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide, an agonist of the alpha7 nicotinic acetylcholine receptor, for the potential treatment of cognitive deficits in schizophrenia: synthesis and structure--activity relationship.

Wishka DG, Walker DP, Yates KM, Reitz SC, Jia S, Myers JK, Olson KL, Jacobsen EJ, Wolfe ML, Groppi VE, Hanchar AJ, Thornburgh BA, Cortes-Burgos LA, Wong EH, Staton BA, Raub TJ, Higdon NR, Wall TM, Hurst RS, Walters RR, Hoffmann WE, Hajos M, Franklin S, Carey G, Gold LH, Cook KK, Sands SB, Zhao SX, Soglia JR, Kalgutkar AS, Arneric SP, Rogers BN.

J Med Chem. 2006 Jul 13;49(14):4425-36.

PMID:
16821801
21.

A novel positive allosteric modulator of the alpha7 neuronal nicotinic acetylcholine receptor: in vitro and in vivo characterization.

Hurst RS, Hajós M, Raggenbass M, Wall TM, Higdon NR, Lawson JA, Rutherford-Root KL, Berkenpas MB, Hoffmann WE, Piotrowski DW, Groppi VE, Allaman G, Ogier R, Bertrand S, Bertrand D, Arneric SP.

J Neurosci. 2005 Apr 27;25(17):4396-405.

22.

Anxiolytic-like effects of the corticotropin-releasing factor1 (CRF1) antagonist DMP904 [4-(3-pentylamino)-2,7-dimethyl-8-(2-methyl-4-methoxyphenyl)-pyrazolo-[1,5-a]-pyrimidine] administered acutely or chronically at doses occupying central CRF1 receptors in rats.

Lelas S, Wong H, Li YW, Heman KL, Ward KA, Zeller KL, Sieracki KK, Polino JL, Godonis HE, Ren SX, Yan XX, Arneric SP, Robertson DW, Hartig PR, Grossman S, Trainor GL, Taub RA, Zaczek R, Gilligan PJ, McElroy JF.

J Pharmacol Exp Ther. 2004 Apr;309(1):293-302. Epub 2004 Jan 23.

PMID:
14742750
23.

Enhanced attention in rhesus monkeys as a common factor for the cognitive effects of drugs with abuse potential.

Bain JN, Prendergast MA, Terry AV Jr, Arneric SP, Smith MA, Buccafusco JJ.

Psychopharmacology (Berl). 2003 Sep;169(2):150-60. Epub 2003 May 27.

PMID:
12768267
24.

Imidazo[4,5-c]pyridines as corticotropin releasing factor receptor ligands.

Arvanitis AG, Rescinito JT, Arnold CR, Wilde RG, Fitzgerald LW, Zaczek R, Hartig PR, Grossman S, Arneric SP, Gilligan PJ, Olson RE, Robertson DW.

Bioorg Med Chem Lett. 2003 Jan 6;13(1):129-31.

PMID:
12467632
25.

Imidazo[4,5-b]pyridines as corticotropin releasing factor receptor ligands.

Arvanitis AG, Rescinito JT, Arnold CR, Wilde RG, Cain GA, Sun JH, Yan JS, Teleha CA, Fitzgerald LW, McElroy J, Zaczek R, Hartig PR, Grossman S, Arneric SP, Gilligan PJ, Olson RE, Robertson DW.

Bioorg Med Chem Lett. 2003 Jan 6;13(1):125-8.

PMID:
12467631
26.

Expression of the alpha4 isoform of the nicotinic acetylcholine receptor in the fetal human cerebral cortex.

Schröder H, Schütz U, Burghaus L, Lindstrom J, Kuryatov A, Monteggia L, deVos RA, van Noort G, Wevers A, Nowacki S, Happich E, Moser N, Arneric SP, Maelicke A.

Brain Res Dev Brain Res. 2001 Dec 14;132(1):33-45.

PMID:
11744105
27.

Antagonism of CRF(2) receptors produces anxiolytic behavior in animal models of anxiety.

Takahashi LK, Ho SP, Livanov V, Graciani N, Arneric SP.

Brain Res. 2001 Jun 1;902(2):135-42.

PMID:
11384606
28.

Attenuation of fear conditioning by antisense inhibition of brain corticotropin releasing factor-2 receptor.

Ho SP, Takahashi LK, Livanov V, Spencer K, Lesher T, Maciag C, Smith MA, Rohrbach KW, Hartig PR, Arneric SP.

Brain Res Mol Brain Res. 2001 Apr 18;89(1-2):29-40.

PMID:
11311973
29.

Synthesis and structure-activity relationships of 5-substituted pyridine analogues of 3.

Lin NH, Li Y, He Y, Holladay MW, Kuntzweiler T, Anderson DJ, Campbell JE, Arneric SP.

Bioorg Med Chem Lett. 2001 Mar 12;11(5):631-3.

PMID:
11266158
30.

Presenilin-1 and -2 are molecular targets for gamma-secretase inhibitors.

Seiffert D, Bradley JD, Rominger CM, Rominger DH, Yang F, Meredith JE Jr, Wang Q, Roach AH, Thompson LA, Spitz SM, Higaki JN, Prakash SR, Combs AP, Copeland RA, Arneric SP, Hartig PR, Robertson DW, Cordell B, Stern AM, Olson RE, Zaczek R.

J Biol Chem. 2000 Nov 3;275(44):34086-91.

31.

Structure-activity studies on a novel series of cholinergic channel activators based on a heteroaryl ether framework.

Lin NH, Abreo MA, Gunn DE, Lebold SA, Lee EL, Wasicak JT, Hettinger AM, Daanen JF, Garvey DS, Campbell JE, Sullivan JP, Williams M, Arneric SP.

Bioorg Med Chem Lett. 1999 Sep 20;9(18):2747-52.

PMID:
10509928
32.

Emerging molecular approaches to pain therapy.

Williams M, Kowaluk EA, Arneric SP.

J Med Chem. 1999 May 6;42(9):1481-500. Review. No abstract available.

PMID:
10229619
33.

Gain of function mutation of the alpha7 nicotinic receptor: distinct pharmacology of the human alpha7V274T variant.

Briggs CA, McKenna DG, Monteggia LM, Touma E, Roch JM, Arneric SP, Gopalakrishnan M, Sullivan JP.

Eur J Pharmacol. 1999 Feb 5;366(2-3):301-8.

PMID:
10082212
34.

Structure-activity studies related to ABT-594, a potent nonopioid analgesic agent: effect of pyridine and azetidine ring substitutions on nicotinic acetylcholine receptor binding affinity and analgesic activity in mice.

Holladay MW, Bai H, Li Y, Lin NH, Daanen JF, Ryther KB, Wasicak JT, Kincaid JF, He Y, Hettinger AM, Huang P, Anderson DJ, Bannon AW, Buckley MJ, Campbell JE, Donnelly-Roberts DL, Gunther KL, Kim DJ, Kuntzweiler TA, Sullivan JP, Decker MW, Arneric SP.

Bioorg Med Chem Lett. 1998 Oct 6;8(19):2797-802.

PMID:
9873625
35.

Synthesis and structure-activity relationships of pyridine-modified analogs of 3-[2-((S)-pyrrolidinyl)methoxy]pyridine, A-84543, a potent nicotinic acetylcholine receptor agonist.

Lin NH, Gunn DE, Li Y, He Y, Bai H, Ryther KB, Kuntzweiler T, Donnelly-Roberts DL, Anderson DJ, Campbell JE, Sullivan JP, Arneric SP, Holladay MW.

Bioorg Med Chem Lett. 1998 Feb 3;8(3):249-54.

PMID:
9871663
36.

Differences between the antinociceptive effects of the cholinergic channel activators A-85380 and (+/-)-epibatidine in rats.

Curzon P, Nikkel AL, Bannon AW, Arneric SP, Decker MW.

J Pharmacol Exp Ther. 1998 Dec;287(3):847-53.

PMID:
9864263
37.

The role of neuronal nicotinic acetylcholine receptors in antinociception: effects of ABT-594.

Decker MW, Curzon P, Holladay MW, Nikkel AL, Bitner RS, Bannon AW, Donnelly-Roberts DL, Puttfarcken PS, Kuntzweiler TA, Briggs CA, Williams M, Arneric SP.

J Physiol Paris. 1998 Jun-Aug;92(3-4):221-4. Review.

PMID:
9789812
38.

ABT-594, a novel cholinergic channel modulator, is efficacious in nerve ligation and diabetic neuropathy models of neuropathic pain.

Bannon AW, Decker MW, Kim DJ, Campbell JE, Arneric SP.

Brain Res. 1998 Aug 10;801(1-2):158-63.

PMID:
9729357
40.

Up-regulation of human alpha7 nicotinic receptors by chronic treatment with activator and antagonist ligands.

Molinari EJ, Delbono O, Messi ML, Renganathan M, Arneric SP, Sullivan JP, Gopalakrishnan M.

Eur J Pharmacol. 1998 Apr 17;347(1):131-9.

PMID:
9650859
41.

Antinociceptive effects of the novel neuronal nicotinic acetylcholine receptor agonist, ABT-594, in mice.

Decker MW, Bannon AW, Buckley MJ, Kim DJ, Holladay MW, Ryther KB, Lin NH, Wasicak JT, Williams M, Arneric SP.

Eur J Pharmacol. 1998 Apr 3;346(1):23-33.

PMID:
9617748
42.

Age-related differences in distractibility and response to methylphenidate in monkeys.

Prendergast MA, Jackson WJ, Terry AV Jr, Kille NJ, Arneric SP, Decker MW, Buccafusco JJ.

Cereb Cortex. 1998 Mar;8(2):164-72.

PMID:
9542895
43.

ABT-594 [(R)-5-(2-azetidinylmethoxy)-2-chloropyridine]: a novel, orally effective antinociceptive agent acting via neuronal nicotinic acetylcholine receptors: II. In vivo characterization.

Bannon AW, Decker MW, Curzon P, Buckley MJ, Kim DJ, Radek RJ, Lynch JK, Wasicak JT, Lin NH, Arnold WH, Holladay MW, Williams M, Arneric SP.

J Pharmacol Exp Ther. 1998 May;285(2):787-94.

PMID:
9580627
44.

ABT-594 [(R)-5-(2-azetidinylmethoxy)-2-chloropyridine]: a novel, orally effective analgesic acting via neuronal nicotinic acetylcholine receptors: I. In vitro characterization.

Donnelly-Roberts DL, Puttfarcken PS, Kuntzweiler TA, Briggs CA, Anderson DJ, Campbell JE, Piattoni-Kaplan M, McKenna DG, Wasicak JT, Holladay MW, Williams M, Arneric SP.

J Pharmacol Exp Ther. 1998 May;285(2):777-86.

PMID:
9580626
45.

Central nicotinic receptor agonists ABT-418, ABT-089, and (-)-nicotine reduce distractibility in adult monkeys.

Prendergast MA, Jackson WJ, Terry AV Jr, Decker MW, Arneric SP, Buccafusco JJ.

Psychopharmacology (Berl). 1998 Mar;136(1):50-8.

PMID:
9537682
46.

Identification and initial structure-activity relationships of (R)-5-(2-azetidinylmethoxy)-2-chloropyridine (ABT-594), a potent, orally active, non-opiate analgesic agent acting via neuronal nicotinic acetylcholine receptors.

Holladay MW, Wasicak JT, Lin NH, He Y, Ryther KB, Bannon AW, Buckley MJ, Kim DJ, Decker MW, Anderson DJ, Campbell JE, Kuntzweiler TA, Donnelly-Roberts DL, Piattoni-Kaplan M, Briggs CA, Williams M, Arneric SP.

J Med Chem. 1998 Feb 12;41(4):407-12.

PMID:
9484491
47.

Broad-spectrum, non-opioid analgesic activity by selective modulation of neuronal nicotinic acetylcholine receptors.

Bannon AW, Decker MW, Holladay MW, Curzon P, Donnelly-Roberts D, Puttfarcken PS, Bitner RS, Diaz A, Dickenson AH, Porsolt RD, Williams M, Arneric SP.

Science. 1998 Jan 2;279(5347):77-81.

48.

ABT-089 [2-methyl-3-(2-(S)-pyrrolidinylmethoxy)pyridine dihydrochloride]: II. A novel cholinergic channel modulator with effects on cognitive performance in rats and monkeys.

Decker MW, Bannon AW, Curzon P, Gunther KL, Brioni JD, Holladay MW, Lin NH, Li Y, Daanen JF, Buccafusco JJ, Prendergast MA, Jackson WJ, Arneric SP.

J Pharmacol Exp Ther. 1997 Oct;283(1):247-58.

PMID:
9336330
49.

ABT-089 [2-methyl-3-(2-(S)-pyrrolidinylmethoxy)pyridine]: I. A potent and selective cholinergic channel modulator with neuroprotective properties.

Sullivan JP, Donnelly-Roberts D, Briggs CA, Anderson DJ, Gopalakrishnan M, Xue IC, Piattoni-Kaplan M, Molinari E, Campbell JE, McKenna DG, Gunn DE, Lin NH, Ryther KB, He Y, Holladay MW, Wonnacott S, Williams M, Arneric SP.

J Pharmacol Exp Ther. 1997 Oct;283(1):235-46.

PMID:
9336329
50.

Supplemental Content

Loading ...
Support Center